Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D2.413 - Diagnostic Value of the Basophil Degranulation Test in High-Risk Drug-Induced Anaphylaxis
D2.415 - DRESS Syndrome induced by Lenalidomide
D2.407 - Treating Through in Pediatric Patients: A Single-Center Experience
D2.408 - Hypersensitivity Reactions to Corticosteroids: A Retrospective Cohort Study
D2.414 - Diagnostic Distribution of Patch, Delayed-Reading Intradermal, and Drug Provocation Tests in Delayed-Type Cutaneous Drug Hypersensitivity
D2.416 - Skin reaction to Kaftrio/Kalydeco (CFTR) in cystic fibrosis: safe reintroduction using an outpatient desensitization protocol
D2.418 - Tolperisone Hypersensitivity: An Underrecognized Drug Allergy in the Context of Widespread Off-Label Use
D2.419 - DRESS syndrome in the context of carbamazepine treatment - case report
D2.420 - A challenging case of cardiotoxicity following palbociclib therapy
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases
D1.444 - Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders
Download the app
The congress at your fingertips
Available on
Download